latest news releases from the newsroom
Intelligent Sports, Inc.
NBA First Round Draft Pick Joins Intelligent Sports
LOS ANGELES, July 29, 2004 (PRIMEZONE) -- Intelligent Sports Inc. (Pink Sheets:IGTS), announced that Kirk Snyder, the 16th overall draft pick of the Utah Jazz in last week's NBA Draft, will become a spokesperson for the company. Snyder, a versatile, multi-skilled player from the University of Nevada, Reno, showcased his talents during the NCAA Tournament and worked his way up the draft.
Paramco Financial Group, Inc.
Paramco Announces New Officers and Directors; Considering New Joint Ventures to Add Revenues
DENVER, June 29, 2004 (PRIMEZONE) -- Paul S. Sidey, President of Paramco Financial Group, Inc. (OTCBB:PFDE), a financial services firm, announced today the election of new Directors to the corporation and the appointment of new officers following the resignation of Douglas G. Gregg as CEO for health reasons that preclude his day to day participation in company operations. Newly elected Directors are Terry Riely and Mike Roth, bringing the present number of Directors to four including Sidey and Gregg.
Telelogic Extends License Deal with European Telecom supplier
MALMO, Sweden, June 29, 2004 (PRIMEZONE) -- Telelogic (Stockholm Exchange:TLOG), the leading global provider of solutions for advanced systems and software development, today announced that it has extended an existing corporate agreement for another year with a leading European telecom supplier. Under the agreement, worth Euro 780,000, the customer gains access to Telelogic's complete set of tools. A minor part of the agreement is related to professional services and training.
BioXell Announces Acquisition of Rights
MILAN, Italy, June 29, 2004 (PRIMEZONE) -- BioXell today announced that it has purchased additional indications from Roche for lead compound BXL 628 which, under the original agreement, was licensed to BioXell for benign prostatic hyperplasia (BPH), secondary hyperparathyroidism, transplant rejection and type I diabetes. The compound has recently completed a phase II trial in Italy for BPH. Under the new agreement, Roche has granted BioXell exclusive worldwide development rights to BXL 628 for all non-topical and non-dermatological applications.